Results of Operations and Financial Condition. On August 14, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

The filing describes an amended and restated management services agreement for the CEO, Thomas H. Jensen.

Results of Operations and Financial Condition. On March 31, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Entry into a Material Definitive Agreement. On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as def…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. Equity Line of Credit Common Stock Purchase Agreement On January 28, 2026, Allarity Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) with Tumim Stone Capital LLC, a Delaware limited liability company (the “ Investor ”). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor up to the lesser of: (a) $6,000,000 of newly issued shares…

Unregistered Sales of Equity Securities. As previously disclosed, on September 22, 2025, Allarity Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated September 22, 2025 (the “Purchase Agreement”) with a certain accredited investor named therein (the “Investor”), pursuant to which the Company sold 1,562,500 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and/or Pre-Funded Warrants to the Investor, in a private placement…

Chief Financial Officer — Jeffrey S. Ervin: Mr. Jeffrey S. Ervin's role transitioned from part-time to full-time Chief Financial Officer with an updated employment agreement.

Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 22, 2025, Allarity Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain accredited investor named therein (the “Investor”), pursuant to which the Company agreed to sell the Shares and/or Pre-Funded Warrants (as defined below) to the Investor, in a private placement transaction (the “Private Placement”). The initial closing of the Private P…

Unregistered Sales of Equity Securities. The disclosure regarding the Shares and/or Pre-Funded Warrants to be sold and issued under the Purchase Agreement set forth under

Chief Financial Officer — Alexander Epshinsky: The CFO resigned and was replaced by a new part-time CFO.

Director — Joseph W. Vazzano (departing), Jesper Høiland (incoming): Mr. Joseph W. Vazzano resigned as a director, and Mr. Jesper Høiland was appointed to succeed him.

Other Events. On June 4, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing a research collaboration with Indiana Biosciences Research Institute to further advance the understanding of stenoparib’s unique mechanism of action. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On May 9, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Director — Thomas H. Jensen: The change was made to rebalance the Board's classes and is considered administrative.

Results of Operations and Financial Condition. On March 31, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024 and forward-looking statements relating to its first quarter of 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the…

Other Events. On March 3, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing that its board of directors has approved a share repurchase program (the “Share Repurchase Program”), with authorization to repurchase up to $5 million of the Company’s outstanding shares of common stock. The Company intends to fund any repurchases under the Share Repurchase Program with available cash. The timing and amount of any shares repurchased will be determined based on the Co…

Other Events. On February 26, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing the dismissal of the securities class action lawsuit previously referenced in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2024. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Other Events. On February 24, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing a new Phase 2 protocol to advance stenoparib towards FDA approval in advanced ovarian cancer patients. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Other Events. Settlement in Principle As previously disclosed, Allarity Therapeutics, Inc. (the “Company”) has been the subject of an investigation (the “Investigation”) by the Securities and Exchange Commission (the “SEC”) which relates to the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the “FDA”) regarding the Company’s New Drug Application ("NDA") for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. The Company has reache…

Results of Operations and Financial Condition On November 14, 2024, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

President and Chief Development Officer — Jeremy R. Graff: Dr. Jeremy R. Graff was appointed as President and Chief Development Officer of Allarity Therapeutics, Inc.

CFO — Joan Y. Brown: The CFO resigned but was immediately succeeded by a named external hire on the same day, indicating an orderly succession rather than a sudden loss of leadership.

Entry into a Material Definitive Agreement. As previously reported in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2024, on March 19, 2024, Allarity Therapeutics, Inc. (the “Company”), entered into an At-The-Market Issuance Sales Agreement (the “Agreement”) with Ascendiant Capital Markets, LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares (the “Placement Shares”) of the…

Material Modifications to Rights of Security Holders. The disclosure required by this